Morgan Stanley Reiterates Equalweight Rating on Karyopharm Therapeutics (KPTI), 'lack of potential takeout news likely to disappoint'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Karyopharm Therapeutics (KPTI) Wild Ride Occurring as M&A Speculation Proved Wrong Amid Executive Departure - RBC
February 22, 2022 12:40 PM ESTRBC Capital analyst Brian Abrahams weighed in on Karyopharm Therapeutics (NASDAQ: KPTI) amid the recent turbulence in the stock, including the 20% up move on Friday on the conference cancellation, which triggered M&A speculation, and today's 31% downdraft on the departure of CMO Dr. Jatin... More
Pre-Open Stock Movers 02/22: (MTOR) (VEV) (HMHC) Higher; (FIXX) (KPTI) (YNDX) Lower (more...)
February 22, 2022 9:20 AM ESTPre-Open Stock Movers:
Meritor, Inc. (NYSE: MTOR) 44.5% HIGHER; Cummins Inc. (NYSE:... More
Karyopharm Therapeutics (KPTI) CMO has stepped down to pursue other professional opportunities
February 22, 2022 7:12 AM EST(Updated - February 22, 2022 7:23 AM EST)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management. In addition, Jatin Shah, M.D. Executive Vice President and Chief Medical Officer has stepped down to pursue other professional opportunities, but will continue to serve Karyopharm in an advisory capacity.
"As accomplished leaders with proven track... More
Karyopharm Therapeutics (KPTI) CEO Cancels Leerink Conf On Scheduling Difficulties - Bloomberg
February 18, 2022 10:15 AM ESTKaryopharm Therapeutics (NASDAQ: KPTI) CEO Cancels Leerink Conf On Scheduling Difficulties - Bloomberg, Citing Email
... MoreUPDATE: Karyopharm Therapeutics (KPTI) shares gain 13% in early trading, bucking market weakness
February 18, 2022 9:37 AM EST(Updated - February 18, 2022 9:41 AM EST)
Karyopharm Therapeutics (NASDAQ: KPTI) shares gain 13% in early trading, bucking market weakness.
gains tied to news the company canceled from today's fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. This was said... More